Clinical Trial Update: Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Octagam 10% for immune thrombocytopenia in adults has completed. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Octagam 10% (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: Octapharma | Conditions: Immune Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2014-05-08